The Accreditation Council for Medical Affairs (ACMA) announced that it will launch a new Board Certification program focused on biologics and biosimilars in November 2022. The Board Certified Biologics and Biosimilars Specialist (BCBBS) program will be for healthcare professionals (e.g., pharmacists, prescribers, PhDs, Industry/MSLs etc.) with the goal of creating a new industry standard for effective management of biologics.
Read more about the new program here.
Pricing Climate Impacting Commercial Considerations
May 3rd 2024In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.
The State of Mining Data Insights in the Life Sciences Industry – 2024
April 30th 2024A Frost & Sullivan industry-wide survey reveals which insights most pharmaceutical companies have mastered and which are still painful or impossible to extract and details the complexity of the process, the confidence companies have in their findings, and more. Hear Web Sun, President and Co-founder of Komodo Health, share what's driving these challenges and how you can overcome them.